Transcript Profiling of Embryonic Gut Development in Wildtype and Ret-Deficient Mice
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hyperactivated Wnt-Β-Catenin Signaling in the Absence of Sfrp1 and Sfrp5 Disrupts Trophoblast Differentiation Through Repressio
Bao et al. BMC Biology (2020) 18:151 https://doi.org/10.1186/s12915-020-00883-4 RESEARCH ARTICLE Open Access Hyperactivated Wnt-β-catenin signaling in the absence of sFRP1 and sFRP5 disrupts trophoblast differentiation through repression of Ascl2 Haili Bao1,2,3†, Dong Liu2†, Yingchun Xu2, Yang Sun2, Change Mu2, Yongqin Yu2, Chunping Wang2, Qian Han2, Sanmei Liu2, Han Cai1,2, Fan Liu2, Shuangbo Kong1,2, Wenbo Deng1,2, Bin Cao1,2, Haibin Wang1,2*, Qiang Wang3,4* and Jinhua Lu1,2* Abstract Background: Wnt signaling is a critical determinant for the maintenance and differentiation of stem/progenitor cells, including trophoblast stem cells during placental development. Hyperactivation of Wnt signaling has been shown to be associated with human trophoblast diseases. However, little is known about the impact and underlying mechanisms of excessive Wnt signaling during placental trophoblast development. Results: In the present work, we observed that two inhibitors of Wnt signaling, secreted frizzled-related proteins 1 and 5 (Sfrp1 and Sfrp5), are highly expressed in the extraembryonic trophoblast suggesting possible roles in early placental development. Sfrp1 and Sfrp5 double knockout mice exhibited disturbed trophoblast differentiation in the placental ectoplacental cone (EPC), which contains the precursors of trophoblast giant cells (TGCs) and spongiotrophoblast cells. In addition, we employed mouse models expressing a truncated β-catenin with exon 3 deletion globally and trophoblast-specifically, as well as trophoblast stem cell lines, and unraveled that hyperactivation of canonical Wnt pathway exhausted the trophoblast precursor cells in the EPC, resulting in the overabundance of giant cells at the expense of spongiotrophoblast cells. -
UNIVERSITY of CALIFORNIA, IRVINE Combinatorial Regulation By
UNIVERSITY OF CALIFORNIA, IRVINE Combinatorial regulation by maternal transcription factors during activation of the endoderm gene regulatory network DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biological Sciences by Kitt D. Paraiso Dissertation Committee: Professor Ken W.Y. Cho, Chair Associate Professor Olivier Cinquin Professor Thomas Schilling 2018 Chapter 4 © 2017 Elsevier Ltd. © 2018 Kitt D. Paraiso DEDICATION To the incredibly intelligent and talented people, who in one way or another, helped complete this thesis. ii TABLE OF CONTENTS Page LIST OF FIGURES vii LIST OF TABLES ix LIST OF ABBREVIATIONS X ACKNOWLEDGEMENTS xi CURRICULUM VITAE xii ABSTRACT OF THE DISSERTATION xiv CHAPTER 1: Maternal transcription factors during early endoderm formation in 1 Xenopus Transcription factors co-regulate in a cell type-specific manner 2 Otx1 is expressed in a variety of cell lineages 4 Maternal otx1 in the endodermal conteXt 5 Establishment of enhancers by maternal transcription factors 9 Uncovering the endodermal gene regulatory network 12 Zygotic genome activation and temporal control of gene eXpression 14 The role of maternal transcription factors in early development 18 References 19 CHAPTER 2: Assembly of maternal transcription factors initiates the emergence 26 of tissue-specific zygotic cis-regulatory regions Introduction 28 Identification of maternal vegetally-localized transcription factors 31 Vegt and OtX1 combinatorially regulate the endodermal 33 transcriptome iii -
X Chromosome Dosage of Histone Demethylase KDM5C Determines Sex Differences in Adiposity
X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity Jenny C. Link, … , Arthur P. Arnold, Karen Reue J Clin Invest. 2020. https://doi.org/10.1172/JCI140223. Research Article Genetics Metabolism Graphical abstract Find the latest version: https://jci.me/140223/pdf The Journal of Clinical Investigation RESEARCH ARTICLE X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity Jenny C. Link,1 Carrie B. Wiese,2 Xuqi Chen,3 Rozeta Avetisyan,2 Emilio Ronquillo,2 Feiyang Ma,4 Xiuqing Guo,5 Jie Yao,5 Matthew Allison,6 Yii-Der Ida Chen,5 Jerome I. Rotter,5 Julia S. El -Sayed Moustafa,7 Kerrin S. Small,7 Shigeki Iwase,8 Matteo Pellegrini,4 Laurent Vergnes,2 Arthur P. Arnold,3 and Karen Reue1,2 1Molecular Biology Institute, 2Human Genetics, David Geffen School of Medicine, 3Integrative Biology and Physiology, and 4Molecular, Cellular and Developmental Biology, UCLA, Los Angeles, California, USA. 5Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA. 6Division of Preventive Medicine, School of Medicine, UCSD, San Diego, California, USA. 7Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom. 8Human Genetics, Medical School, University of Michigan, Ann Arbor, Michigan, USA. Males and females differ in body composition and fat distribution. Using a mouse model that segregates gonadal sex (ovaries and testes) from chromosomal sex (XX and XY), we showed that XX chromosome complement in combination with a high-fat diet led to enhanced weight gain in the presence of male or female gonads. -
1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A -
Epigenetic Services Citations
Active Motif Epigenetic Services Publications The papers below contain data generated by Active Motif’s Epigenetic Services team. To learn more about our services, please give us a call or visit us at www.activemotif.com/services. Technique Target Journal Year Reference Justin C. Boucher et al. CD28 Costimulatory Domain- ATAC-Seq, Cancer Immunol. Targeted Mutations Enhance Chimeric Antigen Receptor — 2021 RNA-Seq Res. T-cell Function. Cancer Immunol. Res. doi: 10.1158/2326- 6066.CIR-20-0253. Satvik Mareedu et al. Sarcolipin haploinsufficiency Am. J. Physiol. prevents dystrophic cardiomyopathy in mdx mice. RNA-Seq — Heart Circ. 2021 Am J Physiol Heart Circ Physiol. doi: 10.1152/ Physiol. ajpheart.00601.2020. Gabi Schutzius et al. BET bromodomain inhibitors regulate Nature Chemical ChIP-Seq BRD4 2021 keratinocyte plasticity. Nat. Chem. Biol. doi: 10.1038/ Biology s41589-020-00716-z. Siyun Wang et al. cMET promotes metastasis and ChIP-qPCR FOXO3 J. Cell Physiol. 2021 epithelial-mesenchymal transition in colorectal carcinoma by repressing RKIP. J. Cell Physiol. doi: 10.1002/jcp.30142. Sonia Iyer et al. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of ATAC-Seq — Cancer Discovery 2021 Combination Immunotherapy. Cancer Discov. doi: doi: 10.1158/2159-8290 Vinod Krishna et al. Integration of the Transcriptome and Genome-Wide Landscape of BRD2 and BRD4 Binding BRD2, BRD4, RNA Motifs Identifies Key Superenhancer Genes and Reveals ChIP-Seq J. Immunol. 2021 Pol II the Mechanism of Bet Inhibitor Action in Rheumatoid Arthritis Synovial Fibroblasts. J. Immunol. doi: doi: 10.4049/ jimmunol.2000286. Daniel Haag et al. -
E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the EGFR and C-MET Oncogenes by Destabilizing the Histone
Published OnlineFirst January 16, 2018; DOI: 10.1158/0008-5472.CAN-17-2118 Cancer Molecular Cell Biology Research E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the EGFR and c-MET Oncogenes by Destabilizing the Histone Demethylase KDM5C Xiaohua Chen1,2, Jun Xian Loo1, Xin Shi1, Wenjun Xiong1,3, Yong Guo4, Haiqiang Ke1, Mingkun Yang5, Yanping Jiang6, Siyu Xia1, Min Zhao1, Shan Zhong1, Chunjiang He1, Li Fu7, and Feng Li1 Abstract The high-risk (HR) human papillomaviruses (HPV) are caus- enhancers in the proto-oncogenes EGFR and c-MET. Ectopic ative agents of anogenital tract dysplasia and cancers and a fraction KDM5C dampened these super-enhancers and reduced the of head and neck cancers. The HR HPV E6 oncoprotein possesses expression of proto-oncogenes. This effect was likely mediated canonical oncogenic functions, such as p53 degradation and by modulating H3K4me3/H3K4me1 dynamics and decreasing telomerase activation. It is also capable of stimulating expression bidirectional enhancer RNA transcription. Depletion of KDM5C of several oncogenes, but the molecular mechanism underlying or HPV16 E6 expression activated these two super-enhancers. these events is poorly understood. Here, we provide evidence that These results illuminate a pivotal relationship between the onco- HPV16 E6 physically interacts with histone H3K4 demethylase genic E6 proteins expressed by HR HPV isotypes and epigenetic KDM5C, resulting in its degradation in an E3 ligase E6AP- and activation of super-enhancers in the genome that drive expression proteasome-dependent manner. Moreover, we found that of key oncogenes like EGFR and c-MET. HPV16-positive cancer cell lines exhibited lower KDM5C protein Significance: This study suggests a novel explanation for why levels than HPV-negative cancer cell lines. -
The University of Chicago Genetic Services Laboratories Labolaboratories 5841 S
The University of Chicago Genetic Services Laboratories LaboLaboratories 5841 S. Maryland Ave., Rm. G701, MC 0077, Chicago, Illinois 60637 Local: (773) CLIA #: 14D0917593 CAP #: 18827-49 Next Generation Sequencing Panels for Non-syndromic Intellectual Disability Intellectual disability (ID), sometimes also referred to as „mental retardation‟ and „cognitive disability‟, is a lifelong disability that presents in infancy or the early childhood years and is typically measured in three domains: intelligence (IQ), adaptive behavior and systems of support [1]. The term „global developmental delay‟ is typically reserved for younger children (less than 5 years of age), whereas the term ID is typically applied to older children when IQ testing is valid and reliable [2]. Non-syndromic ID refers to the presence of ID without accompanying additional physical, neurological, and/or metabolic abnormalities. The prevalence of ID (syndromic and non-syndromic) is estimated to be between 1% - 3%. In general, there is wide variation in the causes of ID: 18 – 44% of cases have exogenous causes (like teratogen exposure or infection) and 17 – 47% have genetic causes [1]. X-linked mental retardation (XLMR) affects between 1/600- 1/1000 males and a substantial number of females [3]. The etiology remains unknown in up to 80% of cases with mild intellectual disability [4]. Depending on the underlying etiology, the recurrence risk can vary between the background and 50%. The best approach to the genetic evaluation of a child with ID is to do a careful history, 3- generation family history, and dysmorphologic and neurologic examination. Based on this alone, a geneticist will suspect or establish a diagnosis in as many as two thirds of cases [2]. -
Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer
life Article Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer Dehua Liu 1 , Chenyu Sun 2 , Nahyun Kim 2 , Chandur Bhan 2, John Pocholo Whitaker Tuason 2, Yue Chen 3, Shaodi Ma 4, Yuting Huang 5 , Ce Cheng 6,7, Qin Zhou 8 and Kaiguang Zhang 1,* 1 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; [email protected] 2 Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, IL 60657, USA; [email protected] (C.S.); [email protected] (N.K.); [email protected] (C.B.); [email protected] (J.P.W.T.) 3 Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, Hefei 230032, China; [email protected] 4 Department of Epidemiology and Health Statistics, School of Public Health Anhui Medical University, Hefei 230032, China; [email protected] 5 University of Maryland Medical Center Midtown Campus, Baltimore, MD 21201, USA; [email protected] 6 The University of Arizona College of Medicine, Banner University Medical Center at South Campus, Tucson, AZ 85724, USA; [email protected] 7 Banner-University Medical Center South, Tucson, AZ 85713, USA 8 Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA; [email protected] * Correspondence: [email protected]; Tel.: +86-138-5517-0097 Citation: Liu, D.; Sun, C.; Kim, N.; Abstract: Gastric cancer (GC) is the fifth most common cancer globally. Secreted frizzled-related Bhan, C.; Tuason, J.P.W.; Chen, Y.; Ma, proteins (SFRP) are important elements associated with the Wnt signaling pathway, and its dysregu- S.; Huang, Y.; Cheng, C.; Zhou, Q.; lated expression is found in multiple cancers. -
Regulation of ZMYND8 to Treat Cancer
molecules Review Regulation of ZMYND8 to Treat Cancer Yun Chen 1,2 , Ya-Hui Tsai 1,2,* and Sheng-Hong Tseng 1,3,* 1 Department of Surgery, Far Eastern Memorial Hospital, Pan-Chiao, New Taipei 220, Taiwan; [email protected] 2 Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li, Taoyuan 320, Taiwan 3 Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan * Correspondence: [email protected] (Y.-H.T.); [email protected] (S.-H.T.); Tel.: +886-2-89-667-000 (ext. 2923) (Y.-H.T.); +886-2-23-123-456 (ext. 65110) (S.-H.T.) Abstract: Zinc finger myeloid, nervy, and deformed epidermal autoregulatory factor 1-type con- taining 8 (Zinc finger MYND-type containing 8, ZMYND8) is a transcription factor, a histone H3- interacting protein, and a putative chromatin reader/effector that plays an essential role in regulating transcription during normal cellular growth. Mutations and altered expression of ZMYND8 are associated with the development and progression of cancer. Increased expression of ZMYND8 is linked to breast, prostate, colorectal, and cervical cancers. It exerts pro-oncogenic effects in breast and prostate cancers, and it promotes angiogenesis in zebrafish, as well as in breast and prostate cancers. In contrast, downregulation of ZMYND8 is also reported in breast, prostate, and nasopharyngeal cancers. ZMYND8 acts as a tumor suppressor in breast and prostate cancers, and it inhibits tumor growth by promoting differentiation; inhibiting proliferation, cell-cycle progression, invasiveness, and metastasis; and maintaining the epithelial phenotype in various types of cancers. These data together suggest that ZMYND8 is important in tumorigenesis; however, the existing data are con- tradictory. -
X- and Y-Linked Chromatin-Modifying Genes As Regulators of Sex-Specific Cancer Incidence and Prognosis
Author Manuscript Published OnlineFirst on July 30, 2020; DOI: 10.1158/1078-0432.CCR-20-1741 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. X- and Y-linked chromatin-modifying genes as regulators of sex- specific cancer incidence and prognosis Rossella Tricarico1,2,*, Emmanuelle Nicolas1, Michael J. Hall 3, and Erica A. Golemis1,* 1Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA; 2Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy; 3Cancer Prevention and Control Program, Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA Running title: Allosomally linked epigenetic regulators in cancer Conflict Statement: The authors declare no conflict of interest. Funding: The authors are supported by NIH DK108195 and CA228187 (to EAG), by NCI Core Grant CA006927 (to Fox Chase Cancer Center), and by a Marie Curie Individual Fellowship from the Horizon 2020 EU Program (to RT). * Correspondence should be directed to: Erica A. Golemis Fox Chase Cancer Center 333 Cottman Ave. Philadelphia, PA 19111 USA [email protected] (215) 728-2860 or Rossella Tricarico Department of Biology and Biotechnology University of Pavia Via Ferrata 9, 27100 Pavia, Italy [email protected] +39 340-2429631 1 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 30, 2020; DOI: 10.1158/1078-0432.CCR-20-1741 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Biological sex profoundly conditions organismal development and physiology, imposing wide-ranging effects on cell signaling, metabolism, and immune response. -
Target Gene Gene Description Validation Diana Miranda
Supplemental Table S1. Mmu-miR-183-5p in silico predicted targets. TARGET GENE GENE DESCRIPTION VALIDATION DIANA MIRANDA MIRBRIDGE PICTAR PITA RNA22 TARGETSCAN TOTAL_HIT AP3M1 adaptor-related protein complex 3, mu 1 subunit V V V V V V V 7 BTG1 B-cell translocation gene 1, anti-proliferative V V V V V V V 7 CLCN3 chloride channel, voltage-sensitive 3 V V V V V V V 7 CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like V V V V V V V 7 DUSP10 dual specificity phosphatase 10 V V V V V V V 7 MAP3K4 mitogen-activated protein kinase kinase kinase 4 V V V V V V V 7 PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) V V V V V V V 7 PPP2R5C protein phosphatase 2, regulatory subunit B', gamma V V V V V V V 7 PTPN4 protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) V V V V V V V 7 EZR ezrin V V V V V V 6 FOXO1 forkhead box O1 V V V V V V 6 ANKRD13C ankyrin repeat domain 13C V V V V V V 6 ARHGAP6 Rho GTPase activating protein 6 V V V V V V 6 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 V V V V V V 6 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like V V V V V V 6 BRMS1L breast cancer metastasis-suppressor 1-like V V V V V V 6 CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) V V V V V V 6 CTDSP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 V V V V V V 6 DCX doublecortin V V V V V V 6 ENAH enabled homolog (Drosophila) V V V V V V 6 EPHA4 EPH receptor A4 V V V V V V 6 FOXP1 forkhead box P1 V -
The Emerging Role of KDM5A in Human Cancer
Yang et al. J Hematol Oncol (2021) 14:30 https://doi.org/10.1186/s13045-021-01041-1 REVIEW Open Access The emerging role of KDM5A in human cancer Guan‑Jun Yang1,2,3,4 , Ming‑Hui Zhu1,2,3, Xin‑Jiang Lu1,2,3, Yan‑Jun Liu5, Jian‑Fei Lu1,2,3, Chung‑Hang Leung4*, Dik‑Lung Ma6* and Jiong Chen1,2,3* Abstract Histone methylation is a key posttranslational modifcation of chromatin, and its dysregulation afects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulation, and epigenetic inherit‑ ance. Variations in the pattern of histone methylation infuence both physiological and pathological events. Lysine‑ specifc demethylase 5A (KDM5A, also known as JARID1A or RBP2) is a KDM5 Jumonji histone demethylase subfamily member that erases di‑ and tri‑methyl groups from lysine 4 of histone H3. Emerging studies indicate that KDM5A is responsible for driving multiple human diseases, particularly cancers. In this review, we summarize the roles of KDM5A in human cancers, survey the feld of KDM5A inhibitors including their anticancer activity and modes of action, and the current challenges and potential opportunities of this feld. Keywords: KDM5A, Cancer, Jumonji C domain, Histone methylation, Drug resistance, Targeted therapy Background NUP98 and KDM5A, mediates hematopoietic cell prolif- Lysine-specifc demethylase 5A (KDM5A), also named eration and alters myelo-erythropoietic diferentiation via Jumonji/ARID domain-containing protein 1A (JARID1A) demethylating H3K4me2/3 [14–17]. In terms of mecha- or retinoblastoma-binding protein 2 (RBP2), origi- nism, KDM5A and its fusion gene Fe(II)-dependently nally reported as a retinoblastoma protein (RB) pocket catalyzes oxidative decarboxylation of 2OG with con- domain-binding protein in 2001 [1], is a Fe(II)- and sumption of O2 to generate a reactive iron(IV)-oxo inter- α-ketoglutaric acid (2OG)-dependent JmjC-containing mediate, carbon dioxide, and succinate.